 |
|
MediGene nominates Dr. Thomas Werner to the Supervisory Board more |
|
|
MediGene AG presents future business plan at annual analyst conference more |
|
|
MediGene AG Decides on a Revision of the Development Plans for EndoTAGTM-1 and RhuDexTM, and Downsizes its Executive Board more |
|
|
MediGene AG Reports First Nine Months of 2009: Increase in Revenue and Reduction of Loss more |
|
|
|
|
Drugs for the market
MediGene's vision is the expansion of the potentials in medicine
by means of utilizing biotechnology in a responsible manner.
We apply state-of-the-art technologies in the development of
innovative drugs for the treatment of cancer and autoimmune
diseases. MediGene pursues the strategy of integrating all core
areas of a modern biopharmaceuticals company from research to
drug development and commercialization.
|
|
|
